The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Open accessAbstract
Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from minor clones. We hypothesize that combinatorial targeting of AML cells can enhance therapeutic efficacy without increasing toxicity. To identify target antigen combinations specific for AML and leukemic stem cells, we generated a detailed protein expression profile based on flow cytometry of primary AML (n = 356) and normal bone marrow samples (n = 34), and a recently reported integrated normal tissue proteomic data set. We analyzed antigen expression levels of CD33, CD123, CLL1, TIM3, CD244 and CD7 on AML bulk and leukemic stem cells at initial diagnosis (n = 302) and relapse (n = 54). CD33, CD123, CLL1, TIM3 and CD244 were ubiquitously expressed on AML bulk cells at initial diagnosis and relapse, irrespective of genetic characteristics. For each analyzed target, we found additional expression in different populations of normal hematopoiesis. Analyzing the coexpression of our six targets in all dual combinations (n = 15), we found CD33/TIM3 and CLL1/TIM3 to be highly positive in AML compared with normal hematopoiesis and non-hematopoietic tissues. Our findings indicate that combinatorial targeting of CD33/TIM3 or CLL1/TIM3 may enhance therapeutic efficacy without aggravating toxicity in immunotherapy of AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“T cells could result in on-target toxicity with depletion of TIM3-positive normal T cells [51].”
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Self-citationMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
B lymphocytes: how they develop and function
LeBien, T. W., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-02-078071 · Cited by 1,400
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Self-citationJordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Shlush, L. I., Mitchell, A., Heisler, L., Abelson, S., Ng, S. W. K., Trotman-Grant, A., Medeiros, J. J. F., Rao-Bhatia, A., Jaciw-Zurakowsky, I., Marke, R., et al. (2017) · Nature · doi:10.1038/nature22993 · Cited by 595
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 511
Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Kikushige, Y., Shima, T., Takayanagi, S.-I., Urata, S., Miyamoto, T., Iwasaki, H., Takenaka, K., Teshima, T., Tanaka, T., Inagaki, Y., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.014 · Cited by 477
Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000349 · Cited by 458
van Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., Walsum, M. S.-V., Zweegman, S., Ossenkoppele, G. J., & Jan Schuurhuis, G. (2007) · Blood · doi:10.1182/blood-2007-03-083048 · Cited by 439
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., & Schlossman, S. F. (1984) · Leukemia Research · doi:10.1016/0145-2126(84)90001-8 · Cited by 403
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
Hosen, N., Park, C. Y., Tatsumi, N., Oji, Y., Sugiyama, H., Gramatzki, M., Krensky, A. M., & Weissman, I. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704271104 · Cited by 379
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Ehninger, A., Kramer, M., Röllig, C., Thiede, C., Bornhäuser, M., von Bonin, M., Wermke, M., Feldmann, A., Bachmann, M., Ehninger, G., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.39 · Cited by 355
Perna, F., Berman, S. H., Soni, R. K., Mansilla-Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C. W., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 346
Self-citationLanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., Weissman, I. L., & Majeti, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100551108 · Cited by 311
Kikushige, Y., Miyamoto, T., Yuda, J., Jabbarzadeh-Tabrizi, S., Shima, T., Takayanagi, S.-I., Niiro, H., Yurino, A., Miyawaki, K., Takenaka, K., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.07.011 · Cited by 286
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84813 · Cited by 276
Self-citationCarey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270
Bakker, A. B. H., van den Oudenrijn, S., Bakker, A. Q., Feller, N., van Meijer, M., Bia, J. A., Jongeneelen, M. A. C., Visser, T. J., Bijl, N., Geuijen, C. A. W., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1659 · Cited by 247
Ross, J. F., Wang, H., Behm, F. G., Mathew, P., Wu, M., Booth, R., & Ratnam, M. (1999) · Cancer · Cited by 225
Diermayr, S., Himmelreich, H., Durovic, B., Mathys-Schneeberger, A., Siegler, U., Langenkamp, U., Hofsteenge, J., Gratwohl, A., Tichelli, A., Paluszewska, M., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101311 · Cited by 220
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Bögeholz, J., Köhnke, T., Lichtenegger, F. S., Schneider, S., Metzeler, K. H., Fiegl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-08-523548 · Cited by 208
Self-citationvan Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A. W. M., Zweegman, S., Ossenkoppele, G. J., & Schuurhuis, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404754 · Cited by 193
Coles, S. J., Wang, E. C. Y., Man, S., Hills, R. K., Burnett, A. K., Tonks, A., & Darley, R. L. (2011) · Leukemia · doi:10.1038/leu.2011.1 · Cited by 181
Schnorfeil, F. M., Lichtenegger, F. S., Emmerig, K., Schlueter, M., Neitz, J. S., Draenert, R., Hiddemann, W., & Subklewe, M. S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0189-2 · Cited by 165
Self-citationCD99 is a therapeutic target on disease stem cells in myeloid malignancies
Chung, S. S., Eng, W. S., Hu, W., Khalaj, M., Garrett-Bakelman, F. E., Tavakkoli, M., Levine, R. L., Carroll, M. P., Klimek, V. M., Melnick, A. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2025 · Cited by 160
Tashiro, H., Sauer, T., Shum, T., Parikh, K., Mamonkin, M., Omer, B., Rouce, R. H., Lulla, P., Rooney, C. M., Gottschalk, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.024 · Cited by 160
Gras, S. L., Günthert, U., Stauder, R., Curt, F., Oliferenko, S., Kluin‐Nelemans, H. C., Marie, J., Proctor, S., Jasmin, C., & Smadja‐Joffe, F. (1998) · Blood · doi:10.1182/blood.v91.9.3401 · Cited by 154
Kügler, M., Stein, C., Kellner, C., Mentz, K., Saul, D., Schwenkert, M., Schubert, I. A., Singer, H., Oduncu, F. S., Stockmeyer, B., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08300.x · Cited by 137
Peinert, S., Prince, H. M., Guru, P., Kershaw, M. H., Smyth, M. J., Trapani, J. A., Gambell, P. C., Harrison, S. J., Scott, A. M., Smyth, F. E., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.21 · Cited by 118
Chen, C., Li, K., Jiang, H., Song, F., Gao, H., Pan, X., Shi, B., Bi, Y., Wang, H., Wang, H., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1949-8 · Cited by 100
Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer, F. C., Kern, W., Schoch, C., Kohlmann, A., Hiddemann, W., Haferlach, T., & Schnittger, S. (2005) · PubMed · Cited by 99
Self-citationLaborda, E., Mazagova, M., Shao, S., Wang, X., Quirino, H., Woods, A. C., Hampton, E. N., Rodgers, D. T., Kim, C., Schultz, P. G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112259 · Cited by 84
Silva, I. G., Gibbs, B. F., Bardelli, M., Varani, L., & Sumbayev, V. V. (2015) · Oncotarget · doi:10.18632/oncotarget.5257 · Cited by 59
Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia
Kikushige, Y., & Miyamoto, T. (2015) · Oncology · doi:10.1159/000431062 · Cited by 54
Targeting CD157 in AML using a novel, Fc-engineered antibody construct
Krupka, C., Lichtenegger, F. S., Köhnke, T., Boegeholz, J., Bücklein, V., Roiss, M., Altmann, T., Do, T. U., Dusek, R. L., Wilson, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16060 · Cited by 36
Self-citationZhang, F., Liu, X., Chen, C., Zhu, J., Yu, Z., Xie, J., Xie, L., Bai, H., Zhang, Y., Fang, X., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.151555 · Cited by 33
Self-citationCD38 in Hematopoietic Malignancies
Konopleva, M. Y., Rissling, I., & Andreeff, M. (2000) · KARGER eBooks · doi:10.1159/000058769 · Cited by 27
TIM3 expression by leukemic and non‐leukemic myeloblasts
Roth, C. G., Garner, K., Eyck, S. T., Boyiadzis, M. M., Kane, L., & Craig, F. E. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21080 · Cited by 22
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
“showed that CLL-1 was increased after chemotherapy (371), others showed that there is no difference between CLL-1 expression at diagnosis and at relapse (415) or even detected a decreased CLL-1 expression at relapse (370).”
BackgroundTIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 341
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Metadata
- Authors
- Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., Kerbs, P., Schneider, S., Metzeler, K. H., Spiekermann, K., Hiddemann, W., Greif, P. A., Herold, T., Sadelain, M., & Subklewe, M.
- Venue
- Leukemia
- Published
- 2018-06-26
- Volume
- 33
- Issue
- 1
- Pages
- 64-74
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2811405063
- Cited by
- 336
- References
- 53
- FWCI
- 15.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.